全文获取类型
收费全文 | 834篇 |
免费 | 57篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 59篇 |
妇产科学 | 16篇 |
基础医学 | 81篇 |
口腔科学 | 15篇 |
临床医学 | 73篇 |
内科学 | 240篇 |
皮肤病学 | 51篇 |
神经病学 | 28篇 |
特种医学 | 84篇 |
外科学 | 133篇 |
综合类 | 22篇 |
预防医学 | 22篇 |
眼科学 | 8篇 |
药学 | 35篇 |
中国医学 | 2篇 |
肿瘤学 | 30篇 |
出版年
2021年 | 7篇 |
2020年 | 7篇 |
2019年 | 10篇 |
2018年 | 9篇 |
2017年 | 13篇 |
2016年 | 9篇 |
2015年 | 14篇 |
2014年 | 19篇 |
2013年 | 28篇 |
2012年 | 19篇 |
2011年 | 23篇 |
2010年 | 38篇 |
2009年 | 35篇 |
2008年 | 32篇 |
2007年 | 27篇 |
2006年 | 26篇 |
2005年 | 22篇 |
2004年 | 20篇 |
2003年 | 32篇 |
2002年 | 23篇 |
2001年 | 12篇 |
2000年 | 14篇 |
1999年 | 17篇 |
1998年 | 23篇 |
1997年 | 43篇 |
1996年 | 36篇 |
1995年 | 22篇 |
1994年 | 26篇 |
1993年 | 23篇 |
1992年 | 23篇 |
1991年 | 12篇 |
1990年 | 20篇 |
1989年 | 36篇 |
1988年 | 20篇 |
1987年 | 19篇 |
1986年 | 24篇 |
1985年 | 22篇 |
1984年 | 12篇 |
1983年 | 5篇 |
1982年 | 4篇 |
1981年 | 8篇 |
1980年 | 11篇 |
1979年 | 9篇 |
1978年 | 8篇 |
1977年 | 11篇 |
1976年 | 6篇 |
1975年 | 7篇 |
1973年 | 5篇 |
1971年 | 4篇 |
1970年 | 2篇 |
排序方式: 共有905条查询结果,搜索用时 0 毫秒
71.
72.
AD Collaborative Group Bentham P Gray R Sellwood E Hills R Crome P Raftery J 《Lancet neurology》2008,7(1):41-49
BACKGROUND: Cardiovascular risk factors and a history of vascular disease can increase the risk of Alzheimer's disease (AD). AD is less common in aspirin users than non-users, and there are plausible biological mechanisms whereby aspirin might slow the progression of either vascular or Alzheimer-type pathology. We assessed the benefits of aspirin in patients with AD. METHODS: 310 community-resident patients who had AD and who had no potential indication or definite contraindication for aspirin were randomly assigned to receive open-label aspirin (n=156; one 75-mg enteric-coated tablet per day, to continue indefinitely) or to avoid aspirin (n=154). Primary outcome measures were cognition (assessed with the mini-mental state examination [MMSE]) and functional ability (assessed with the Bristol activities of daily living scale [BADLS]). Secondary outcomes were time to formal domiciliary or institutional care, progress of disability, behavioural symptoms, caregiver wellbeing, and care time. Patients were assessed at 12-week intervals in the first year and once each year thereafter. Analysis of the primary outcome measures was by intention to treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN96337233. FINDINGS: Patients had a median age of 75 years; 156 patients had mild AD, 154 had moderate AD, and 18 had concomitant vascular dementia. Over the 3 years after randomisation, in patients who took aspirin, mean MMSE score was 0.10 points higher (95% CI -0.37 to 0.57; p=0.7) and mean BADLS score was 0.62 points lower (-1.37 to 0.13; p=0.11) than in patients assigned to aspirin avoidance. There were no obvious differences between the groups in any other outcome measurements. 13 (8%) patients on aspirin and two (1%) patients in the control group had bleeds that led to admission to hospital (relative risk=4.4, 95% CI 1.5-12.8; p=0.007); three (2%) patients in the aspirin group had fatal cerebral bleeds. INTERPRETATION: Although aspirin is commonly used in dementia, in patients with typical AD 2 years of treatment with low-dose aspirin has no worthwhile benefit and increases the risk of serious bleeds. 相似文献
73.
D Pathirana A Nast AD Ormerod N Reytan P Saiag CH Smith P Spuls B Rzany 《Journal of the European Academy of Dermatology and Venereology》2010,24(12):1458-1467
Background The development of evidence based guidelines is a demanding and time consuming process. Therefore it is important to share the knowledge and discuss the structure of these guidelines in detail. Objectives To present a method report on the development process of the European evidence based guidelines on the systemic treatment of psoriasis vulgaris with the aim to offer guidance to other guidelines groups with lesser experience and to critically appraise the methodology of the guidelines development process. Methods The guidelines are based on the previously evaluated literature from three European national evidence based guidelines and an additional systematic search and evaluation of new literature. Further steps included a structured consensus conference and a DELPHI procedure to develop the recommendations, as well as several internal and external reviews. All steps were coordinated by the Division of evidence based medicine in cooperation with a group of methodologists. Results A total of 114 studies were included, serving as base for the efficacy chapters of the intervention. The recommendations, based on the efficacy and the level of evidence of the included studies were discussed and finally consented by the guidelines group. After subsequent reviews the guidelines were presented to the European Dermatology Forum, European Academy of Dermatology and Venereology and Union Européenne des Médicins Spécialistes for approval and published in October 2009. Conclusion The development of European evidence based guidelines requires a coordinated structure which can be achieved by the integration of an experienced group of methodologists. Nevertheless further improvements are imaginable and might be considered for an update or other European evidence based guidelines. 相似文献
74.
N Mohebbi R Vargas‐Poussou SCA Hegemann B Schuknecht AD Kistler RP Wüthrich CA Wagner 《Clinical genetics》2013,83(3):274-278
Mohebbi N, Vargas‐Poussou R, Hegemann SCA, Schuknecht B, Kistler AD, Wüthrich RP, Wagner CA. Homozygous and compound heterozygous mutations in the ATP6V1B1 gene in patients with renal tubular acidosis and sensorineural hearing loss. Distal renal tubular acidosis (dRTA) is characterized by the inability to excrete acid in the renal collecting ducts resulting in inappropriately alkaline urine and hyperchloremic (normal anion gap) metabolic acidosis in the context of a normal (or near‐normal) glomerular filtration rate. Inborn dRTA can be due to autosomal dominant or recessive gene defects. Clinical symptoms vary from mild acidosis, incidental detection of kidney stones or renal tract calcification to severe findings such as failure to thrive, severe metabolic acidosis, and nephrocalcinosis. The majority of patients with recessive dRTA present with sensorineural hearing loss (SNHL). Few cases with abnormal widening of the vestibular aqueduct have been described with dRTA. Mutations in three different genes have been identified, namely SLC4A1, ATP6V1B1, and ATP6V0A4. Patients with mutations in the ATP6V1B1 proton pump subunit develop dRTA and in most of the cases sensorineural hearing loss early in childhood. We present two patients from two different and non‐consanguineous families with dRTA and SNHL. Direct sequencing of the ATP6V1B1 gene revealed that one patient harbors two homozygous mutations and the other one is a compound heterozygous. To our knowledge, this is the first case in the literature describing homozygosity in the same dRTA gene on both alleles. 相似文献
75.
Aaron E Boyce Gillian Marshman Richard AD Mills 《The Australasian journal of dermatology》2009,50(3):190-193
Erosive mucosal lichen planus (LP) is a well-established variant of LP characterized by the formation of ulcerative lesions predominantly involving the oral and genital mucosae. Less commonly, this condition may involve oesophageal and/or ocular mucosal surfaces, and case reports within the ophthalmology literature have recently confirmed the potential for this condition to affect the nasolacrimal ducts. We report the case of a woman with severe cicatrizing mucosal LP and ocular symptoms secondary to presumed nasolacrimal duct involvement. We also report the potential for this newly appreciated manifestation of LP to respond to systemic cyclosporin A. 相似文献
76.
77.
Vieri Grandi Antonello Baldo Emilio Berti Pietro Quaglino Serena Rupoli Mauro Alaibac Silvia Alberti-Violetti Paolo Amerio Valeria Brazzelli Pier Luigi Bruni Piergiacomo Calzavara-Pinton Aurora Parodi Emanuele Cozzani Martina Burlando Maria Concetta Fargnoli Daniele Gambini Paolo Iacovelli Alessia Pacifico Caterina Longo Giuseppe Monfrecola Alberico Motolese Giorgio Mozzicafreddo Carlo Cota Paolo Pigatto Alessandro Pileri Paola Savoia Marco Simonacci Marina Venturini Annamaria Offidani Elisa Molinelli Michele Pellegrino Emanuele Trovato Roberta Piccinno Karl Lawrence Nicola Pimpinelli 《Photodermatology, photoimmunology & photomedicine》2021,37(4):334-342
78.
IJ Webb ; CE Eickhoff ; AD Elias ; LJ Ayash ; CA Wheeler ; GN Schwartz ; GD Demetri ; KC Anderson 《Transfusion》1996,36(2):160-167
BACKGROUND: Peripheral blood progenitor cells (PBPCs) are commonly collected and used to reconstitute hematopoiesis after high-dose chemotherapy. However, strategies for optimal collection and assessment of leukapheresis components are not standardized. STUDY DESIGN and METHODS: Hematopoietic progenitor cell assays were performed on 369 leukapheresis components collected from 95 patients who had received doxorubicin-based chemotherapy and/or granulocyte-colony-stimulating factor (G-CSF). Precollection patient hematologic values, leukapheresis collection values, component hematopoietic progenitor cell assays, and patient outcome measures were summarized. The kinetics of mononuclear cell (MNC) and PBPC mobilization were assessed among four patient groups. RESULTS: Patient group was a significant predictor of the peripheral blood MNC count on the day of collection (p<0.0001), and that value was a significant predictor of granulocyte-macrophage– colony-forming unit (CFU-GM) yield (p<0.0001). This relationship between the peripheral blood MNC count on the day of collection and CFU- GM yield differed according to patient group (p<0.0001). CFU-GM made up a larger fraction of peripheral blood MNCs collected from patients who received chemotherapy plus G-CSF than collected from those who received G-CSF alone. Moreover, the peripheral blood MNC count and the corresponding CFU-GM yield increased significantly on consecutive days of collection in patient groups receiving chemotherapy and G-CSF but were unchanged or decreased in patients receiving G-CSF alone. CONCLUSION: The relationship between peripheral blood MNC count and leukapheresis component CFU-GM yield differed significantly between patients who received chemotherapy and G-CSF and those who received G- CSF alone for the mobilization of PBPCs. Patient peripheral blood MNC count and component CFU-GM yield are useful for both assessing and suggesting revisions to PBPC mobilization and collection strategies. 相似文献
79.
80.